NASDAQ
Capital Fund Management S.A. purchased a new stake in Janux Therapeutics, Inc. (NASDAQ: JANX) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commi...
Meyer Andrew Hollman, Chief Business Officer at Janux Therapeutics (JANX 1.70%), exercised 16,665 options and immediately sold the resulting shares for a transaction value of approximately $501,000 on...
Janux Therapeutics Inc. (NASDAQ: JANX) stock hit a 52-week low on Tuesday after the company released updated interim data for its JANX007 Phase 1 program for metastatic castration-resistant prostate c...
Shares of Janux Therapeutics slumped nearly 50% on Tuesday as investors reacted to limited disclosure in the company's early-stage study update for its prostate cancer treatment....
U.S. stock futures were higher this morning, with the Dow futures gaining around 0.1% on Tuesday....
Janux posts what it called ‘positive trial data' for its novel treatment in patients with late-stage prostate cancer....
Ensign Peak Advisors Inc reduced its position in Janux Therapeutics, Inc. (NASDAQ: JANX) by 96.8% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exc...
Janux Therapeutics, Inc. (JANX) Shareholder/Analyst Call Transcript...
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC....
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its p...
No price data available for this timeframe.